PD0325901

Catalog No. A10256

PD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
  • Tzeng SF, .et al. O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer, FASEB J, 2018, Jun 15:fj201800687 PMID: 29906246
  • Fukumoto S, .et al. Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27, Acta Histochem, 2018, Feb;120(2):142-150 PMID: 29397960
  • Yoshiteru Yano, .et al. Non-neural and cardiac differentiating properties of Tbx6-expressing mouse embryonic stem cells, Regenerative Therapy, 2016, 3 (2016) 1-6
Catalog Num A10256
M. Wt 482.2
Formula C16H14F3IN2O4
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 391210-10-9
Synonyms N/A
SMILES C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[[email protected]@H](CO)O
PD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
Targets
MEK (Cell-free assay)
0.33 nM
In vitro DMSO 96 mg/mL (199.09 mM)
Water <1 mg/mL (<1 mM)
Ethanol 40 mg/mL (82.95 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 20.74 mL 103.69 mL 207.38 mL
0.5 mM 4.15 mL 20.74 mL 41.48 mL
1 mM 2.07 mL 10.37 mL 20.74 mL
5 mM 0.41 mL 2.07 mL 4.15 mL

*The above data is based on the productmolecular weight 482.2. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.